TIDMROQ
RNS Number : 8960A
Roquefort Therapeutics PLC
28 September 2022
28 September 2022
Roquefort Therapeutics plc
("Roquefort Therapeutics" or the "Company")
Director/PDMR Shareholding
Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF), the Main Market
listed biotech company focused on developing first in class drugs
in the high value and high growth oncology segment, advises that
Stephen West, Executive Chairman and Dr Simon Sinclair, a
Non-Executive Director have purchased ordinary shares in the
Company in the market, as detailed below:
Number of Ordinary Average Price Total Consideration
Name Shares Paid Per Share Paid
Stephen West 244,656 8.175 pence GBP19,999.79
------------------- ---------------- --------------------
Simon Sinclair 60,415 8.276 pence GBP4,999.97
------------------- ---------------- --------------------
Following the above purchase of shares, Stephen West and Simon
Sinclair hold interests in the following Company securities:
Number of Ordinary % of Issued Share Number of Warrants
Name Shares Held Capital Held
Stephen West 5,313,264 4.11% 7,500,000
------------------- ------------------ -------------------
Simon Sinclair 60,415 0.05% 300,000
------------------- ------------------ -------------------
4,628,485 of Mr West's shares are held in the name of Cresthaven
Investments Pty Ltd ATF the Bellini Trust.
Enquiries:
Roquefort Therapeutics plc
Stephen West (Chairman) / Ajan +44 (0)20 3290
Reginald (CEO) 9339
Hybridan LLP (Joint Broker)
Claire Louise Noyce
Optiva Securities Limited (Joint +44 (0)203 764
Broker) 2341
+44 (0)20 3411
Christian Dennis 1881
Buchanan (Public Relations)
Ben Romney / Jamie Hooper / George +44 (0)20 7466
Beale 5000
LEI: 254900P4SISIWOR9RH34
About Roquefort Therapeutics
Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF) is a Main Market
listed biotech company developing first in class drugs in the high
value and high growth oncology segment prior to partnering or
selling to big pharma.
Since listing in March 2021, Roquefort Therapeutics has
successfully acquired Lyramid Pty Limited, a leader in the
development of medicines for a new therapeutic target, Midkine (a
human growth factor associated with cancer progression), and most
recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor
Sir Martin Evans, which has developed two families of innovative
cell and RNA oncology medicines.
Roquefort Therapeutics' portfolio consists of four fully funded,
novel patent-protected pre-clinical anti-cancer medicines. The
highly complementary profile of four best-in-class medicines
consists of:
-- Midkine antibodies with significant in vivo efficacy and toxicology studies;
-- Midkine RNA therapeutics with novel anti-cancer gene editing action;
-- MK cell therapy with direct and NK-mediated anti-cancer action; and
-- siRNA targeting novel STAT-6 target in solid tumours showing significant in vivo efficacy.
For further information on Roquefort Therapeutics, please visit
www.roquefortplc.com and @RoquefortTherap on Twitter.
This announcement contains inside information for the purposes
of Article 7 of the UK version of Market Regulation (EU) No
596/2014 on Market Abuse as it forms part of UK domestic law by
virtue of the European Union (Withdrawal) Act 2018, as amended ("UK
MAR").
The notification below, made in accordance with the requirements
of the UK MAR, provides further detail:
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS
DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY
ASSOCIATED WITH THEM
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name Stephen West
------------------------------- ----------------------------------------
Reason for the notification
2
-------------------------------------------------------------------------
a) Position/status Executive Chairman
------------------------------- ----------------------------------------
b) Initial notification Initial
/Amendment
------------------------------- ----------------------------------------
Details of the issuer, emission allowance market participant,
3 auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name Roquefort Therapeutics plc
------------------------------- ----------------------------------------
b) LEI 254900P4SISIWOR9RH34
------------------------------- ----------------------------------------
Details of the transaction(s): section to be repeated
4 for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-------------------------------------------------------------------------
a) Description of the Ordinary shares of GBP0.01 par value
financial instrument,
type of instrument ISIN: GB00BMDQ2T15
Identification code
------------------------------- ----------------------------------------
b) Nature of the transaction Purchase of 244,656 ordinary shares
------------------------------- ----------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
------------------------------- ---------------------------- ----------
8.000 pence per share 62,040
8.215 pence per share 60,416
8.000 pence per share 62,040
8.250 pence per share 60,160
----------------------------------------------------------------- ----------
d Aggregated information
- Aggregated volume * 244,656
- Price
* 8.175p
------------------------------- ----------------------------------------
e) Date of the transactions 27 September 2022
------------------------------- ----------------------------------------
f) Place of the transactions London Stock Exchange (XLON); Main
Market
------------------------------- ----------------------------------------
The notification below, made in accordance with the requirements
of the UK MAR, provides further detail:
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS
DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY
ASSOCIATED WITH THEM
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name Dr Simon Sinclair
------------------------------- ----------------------------------------
Reason for the notification
2
-------------------------------------------------------------------------
a) Position/status Non-Executive Director
------------------------------- ----------------------------------------
b) Initial notification Initial
/Amendment
------------------------------- ----------------------------------------
Details of the issuer, emission allowance market participant,
3 auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name Roquefort Therapeutics plc
------------------------------- ----------------------------------------
b) LEI 254900P4SISIWOR9RH34
------------------------------- ----------------------------------------
Details of the transaction(s): section to be repeated
4 for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-------------------------------------------------------------------------
a) Description of the Ordinary shares of GBP0.01 par value
financial instrument,
type of instrument ISIN: GB00BMDQ2T15
Identification code
------------------------------- ----------------------------------------
b) Nature of the transaction Purchase of 60,415 ordinary shares
------------------------------- ----------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
------------------------------- ---------------------------- ----------
8.276 pence per share 60,415
----------------------------------------------------------------- ----------
d Aggregated information
- Aggregated volume * 60,415
- Price
* 8.276p
------------------------------- ----------------------------------------
e) Date of the transactions 27 September 2022
------------------------------- ----------------------------------------
f) Place of the transactions London Stock Exchange (XLON); Main
Market
------------------------------- ----------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHBLGDCGGDDGDR
(END) Dow Jones Newswires
September 28, 2022 02:02 ET (06:02 GMT)
Roquefort Therapeutics (LSE:ROQ)
Historical Stock Chart
From May 2024 to Jun 2024
Roquefort Therapeutics (LSE:ROQ)
Historical Stock Chart
From Jun 2023 to Jun 2024
